TACSTD2 and ovarian carcinoma: However, we found that Nectin-4 is also widely expressed in cervical cancer; Sacituzumab Govitecan is the world’s first and only approved ADC drug targeting Trop-2 for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (Wahby et al., 2021), and the target Trop-2 is also widely expressed in endometrial cancer, ovarian cancer, and cervical cancer; Trastuzumab Deruxtecan also has shown promising activity in various types of late stage solid tumors with ERBB2 expression, including traditionally difficult to treat malignant tumors (AACR, 2023).